ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos351 M212 M230 M268 M308 M1.02 BInvestigación y desarrollo1.12 B856 M700 M801 M775 M3.13 BBeneficio operativo-1.25 B-1.05 B-907 M-260 M-857 M-3.07 BTotal de ingresos no operativos72 M97 M107 M93 M68 M365 MGastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses101 M101 M99 M93 M80 M373 MIngresos/gastos extraordinarios-29 M-4 M8 M0-12 M-8 MBeneficio antes de impuestos-1.18 B-964 M-818 M-187 M-799 M-2.77 BParticipación en los beneficios-9 M-8 M03 M-3 M-8 MImpuestos-64 M7 M7 M13 M27 M54 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-54 M-2 M-34 M-14 M-27 M-77 MBeneficio neto antes de actividades interrumpidas-1.12 B-971 M-825 M-200 M-826 M-2.82 BOperaciones suspendidas——————Beneficio neto-1.12 B-971 M-825 M-200 M-826 M-2.82 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-1.12 B-971 M-825 M-200 M-826 M-2.82 BBeneficio básico por acción-2.91-2.52-2.13-0.51-2.1-7.26Beneficio por acción diluido-2.91-2.52-2.13-0.51-2.1-7.26Número medio de acciones ordinarias384 M386 M388 M390 M389 M1.55 BAcciones diluidas384 M386 M388 M390 M389 M1.55 BEBITDA-1.19 B-1.01 B-851 M-209 M-791 M-2.86 BEBIT-1.25 B-1.05 B-907 M-260 M-857 M-3.07 BCosto de los ingresos739 M90 M119 M207 M452 M868 MOtros costes de producción276 M52 M45 M74 M144 M315 MAmortización y depreciación (flujo de caja)59 M38 M56 M51 M66 M211 M
Moderna Inc
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a respiratory syncytial virus vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.